Overview

Combined Use of Raltitrexed and S-1 as Treatment for Patients With Metastasizing Colorectal Cancer

Status:
Unknown status
Trial end date:
2017-11-01
Target enrollment:
Participant gender:
Summary
The primary endpoint is to evaluate the Median disease progression free survival (mPFS).
Phase:
Phase 2
Details
Lead Sponsor:
Fudan University
Treatments:
Raltitrexed